

Name of the Issuer:	Krsnaa Diagnostics Limited	Last updated on	25-Feb-22
----------------------------	-----------------------------------	------------------------	------------------

1 Type of Issue (PO / FPO)	IPO
-----------------------------------	-----

2 Issue Size (Rs. Cr)	1213.3
- Fresh Issue Size (Rs. Cr)	400.0
- Offer for Sale Component (Rs. Cr)	813.3
Source: Post Issue Monitoring Report	

3 Grade of Issue along with name of the rating agency	
Name	Not Applicable
Grade	Not Applicable

4 Subscription Level (Number of times)	36.05*
Source: Post Issue Monitoring Report	
*The above figure is after technical rejections and includes anchor	

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges	
Particulars	%
(i) allotment in the issue ⁽¹⁾	30.08%
(ii) at the end of the 1st Quarter immediately after the listing of the issue	36.16%
(iii) at the end of 1st FY (March 31, 2022)*	Not Available
(iv) at the end of 2nd FY (March 31, 2023)*	Not Available
(v) at the end of 3rd FY (March 31, 2024)*	Not Available
* QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.	
(1) Source: Minutes of Basis of Allotment. Includes allotment to Anchor Investors	

6 Financials of the issuer			
	(In Rs. Crore)		
Parameters (consolidated)	1st FY (March 31, 2022)*	2nd FY (March 31, 2023)*	3rd FY (March 31, 2024)*
Income from operations	Not Available	Not Available	Not Available
Net Profit for the period	Not Available	Not Available	Not Available
Paid-up equity share capital	Not Available	Not Available	Not Available
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available
* Financials not disclosed as reporting for the relevant fiscal year has not been completed.			

7 Trading Status in the scrip of the issuer	
Company's Equity Shares are listed on both the BSE Limited and the NSE. The Shares have not been suspended or delisted.	
Particulars	Status
(i) at the end of 1st FY (March 31, 2022)*	Not Available
(ii) at the end of 2nd FY (March 31, 2023)*	Not Available
(iii) at the end of 3rd FY (March 31, 2024)*	Not Available
* Trading status not disclosed as the relevant fiscal year has not been completed.	

8 Change in Directors of issuer from the disclosures in the offer document		
Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)*	-	-
(ii) at the end of 2nd FY (March 31, 2023)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2024)*	Not Available	Not Available
# Updated till Feb 25, 2022		
* Changes in Directors not disclosed as the relevant fiscal year has not been completed.		

9 Status of implementation of project/ commencement of commercial production	
(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds				
(i) as disclosed in the offer document				
	(In Rs. Crore)			
Particulars	Total estimated amount/ expenditure	Estimated utilisation from Net Proceeds	Estimated Deployment (Financial Year 2022)	Estimated Deployment (Financial Year 2023)
Finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra	150.81	150.81	125.00	25.81
Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by our Company	146.08	146.08	146.08	0.00
General corporate purposes	81.74	81.74	81.74	0.00
Total	378.63	378.63	352.82	25.81

(ii) Actual utilization	
	(In Rs. Crore)
Particulars	As of September 30, 2021
Finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra	38.79
Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by our Company	142.90
General corporate purposes	0.50
Total	182.19
(iii) Reasons for deviation, if any	None

11 Comments of monitoring agency, if applicable	
(a) Comments on use of funds	Not available
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data

Issue Price (Rs.):	954
Designated Stock Exchange:	NSE
Listing Date:	16-Aug-21

Price parameters	At close of listing day (Aug 16, 2021)	At close of 30th calendar day from listing day (Sep 14, 2021) ⁽¹⁾	At close of 90th calendar day from listing day (Nov 13, 2021) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2022) ⁽³⁾⁽⁴⁾			As at the end of 2nd FY after the listing of the issue (March 31, 2023) ⁽³⁾⁽⁴⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2024) ⁽³⁾⁽⁴⁾		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	987.00	864.15	689.45	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50	16,563.05	17,380.00	18,102.75	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Sectoral Index ⁽⁵⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

- Note:
- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
 - (2) 90th calendar day shall be taken as listing date plus 89 calendar days.
 - (3) High and Low based on intra day prices.
 - (4) Pricing data not disclosed as the relevant fiscal year has not completed.
 - (5) There is no sectoral index

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2022) ⁽²⁾	At the end of 2nd FY (March 31, 2023) ⁽²⁾	At the end of 3rd FY (March 31, 2024) ⁽²⁾
EPS	Issuer:			
	Basic	71.86	Not Available	Not Available
	Diluted	12.25	Not Available	Not Available
	Peer Group:			
	Metropolis Healthcare Limited (Basic)	35.97	Not Available	Not Available
	Metropolis Healthcare Limited (Diluted)	35.79	Not Available	Not Available
P/E	Issuer:			
	Basic	77.88	Not Available	Not Available
	Peer Group:			
	Metropolis Healthcare Limited (Basic)	77.65	Not Available	Not Available
	Dr. Lal Pathlabs Limited (Basic)	94.32	Not Available	Not Available
	Industry Avg:	85.99	Not Available	Not Available
RoNW (%)	Issuer:	79.76%	Not Available	Not Available
	Peer Group:			
	Metropolis Healthcare Limited	25.91	Not Available	Not Available
	Dr. Lal Pathlabs Limited	23.42	Not Available	Not Available
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable
	Issuer:	85.27	Not Available	Not Available
NAV per share	Peer Group:			
	Metropolis Healthcare Limited	138.23	Not Available	Not Available
	Dr. Lal Pathlabs Limited	149.39	Not Available	Not Available
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable

Notes:
 (1) Sourced from Prospectus.
 (2) Information not provided as the relevant fiscal year has not completed
 Key ratios for the Company for 1st FY and 2nd FY stated above are calculated as follows:
 (i) Basic and diluted earnings per Equity Share are based on the Annual Reports for the relevant years
 (ii) P/E - Closing Market Price on BSE as of relevant fiscal year / EPS (diluted); Also disclosed EPS (basic) for the Issuer
 (iii) RoNW - Net profit after tax attributable to the owners divided by net worth at the end of the relevant period
 (iv) NAV per share - Net worth at the end of the relevant period divided by Total Equity Shares Outstanding as of fiscal year end

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
26-Aug-21	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with Government of Punjab ("Agreement") for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company will be inaugurating its first Diagnostics Center of the above mentioned Agreement at Mohali, Punjab on August 31, 2021 which will provide CT Scan, MRI & Pathology Laboratory facilities.
30-Sep-21	Krснаа Diagnostics Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/10/2021, inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of the SEBI (LODR) Regulations, 2015 and all other applicable provisions in this behalf, we wish to inform you that the Meeting of the Board of Directors of Krснаа Diagnostics Limited ("the Company") is scheduled to be held on Monday, 11th October, 2021, through audio-visual means, inter alia, to consider and approve Unaudited (Standalone and Consolidated) Financial Results ("UFR"), for the quarter and six months ending on 30th September, 2021 and to take on record, the Limited Review Report thereon
6-Oct-21	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 submitted
7-Oct-21	Statement Of Investor Complaints For The Quarter Ended September 2021 submitted
11-Oct-21	Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended on 30th September, 2021
11-Oct-21	Change in the Key Managerial Personnel: The resignation of CS Manisha Chitgopkar from the post of Company Secretary and Compliance Officer of the Company effective from closing of business hours on Monday, 11th October, 2021 and appointment of Mr. Nikhil Deshpande as Company Secretary and Key Managerial Personnel pursuant to the provisions of Section 203 of the Companies Act, 2013 and as Compliance Officer effective from Tuesday, 12th October, 2021, pursuant to the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015
11-Oct-21	Pursuant to the provisions of Regulation 32 (1) of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 30th September, 2021.
11-Oct-21	Press Release - Unaudited Financial Results for the quarter and six months ended on 30th September, 2021.
11-Oct-21	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a Earnings Presentation for on Unaudited Financial Results of the Company for the period ended on 30th September, 2021.
11-Oct-21	The resignation of CS Manisha Chitgopkar from the post of Company Secretary and Compliance Officer of the Company effective from closing of business hours on Monday, 11th October, 2021
11-Oct-21	Appointment of Mr. Nikhil Deshpande as Company Secretary and Key Managerial Personnel pursuant to the provisions of Section 203 of the Companies Act, 2013 and as Compliance Officer effective from Tuesday, 12th October, 2021, pursuant to the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015.
13-Oct-21	Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Unaudited Financial Results of the Company for the quarter and six months ended on 30th September, 2021, published in Financial Express (All Editions) and LokSatta (Pune Edition), both dated on 13th October, 2021.
19-Oct-21	Please find enclosed the transcript of the Q2 and H1 FY22 Earnings Conference Call conducted on 12th October, 2021, for your information and records.
9-Nov-21	Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions for the half year ended 30th September, 2021.
12-Nov-21	Pursuant to Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have attached herewith a Report of Monitoring Agency i.e. ICICI Bank Limited for the quarter ended 30th September, 2021.
4-Dec-21	Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"), we would like to inform you that based on CRISIL Rating letter dated 03rd December, 2021, the credit rating of the Company, has been upgraded as per the attached letter. The detailed report on Credit Rating issued by CRISIL is accessible on the following link: https://www.crisil.com/mn/wshare/Ratings/RatingList/RatingDocs/KrsnaaDiagnosticsLimited_December%202021_RR_282773.html
24-Dec-21	Inauguration of Diagnostics Centers under Punjab Radiology and Pathology Project.
3-Jan-22	Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Inauguration Of Diagnostics Centers Under Punjab Radiology and Pathology Project.
5-Jan-22	Pursuant to the provisions of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith the certificates for the quarter ended December 31, 2021, received from KFin Technologies Private Limited (SEBI Registration Number INR000000221), Registrar and Share Transfer Agent of the Company. It is requested to take this information on record and acknowledge receipt of the same.
7-Jan-22	Inauguration of Diagnostics Centers under Punjab Radiology and Pathology Project.
11-Jan-22	Statement Of Investor Complaints For The Quarter Ended December 2021
17-Jan-22	Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"), we would like to inform you that ICRA, has assigned a long-term rating of [ICRA]A (pronounced ICRA A) and a short-term rating of [ICRA]A1 (pronounced ICRA A one) for INR 85.00 Core Line of Credit (LOC) of the Company. The Outlook on the long-term rating is Stable.
22-Jan-22	Inauguration of Diagnostics Center at K. B. Bhatia Hospital, Kuria, Mumbai.

24-Jan-22	Krснаа Diagnostics Lidhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022. Inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of the SEBI (LODR) Regulations, 2015 and all other applicable provisions in this behalf, we wish to inform you that the Meeting of the Board of Directors of Krснаа Diagnostics Limited ("the Company") is scheduled to be held on Monday, 31st January, 2022, through audio-visual means, inter alia, to consider and approve Unaudited (Standalone and Consolidated) Financial Results ("UFR"), for the quarter ended on 31st December, 2021 and to take on record, the Limited Review Report thereon. The Company will hold investor / analyst call post Board Meeting. The details of the said call will be intimated to the stock exchanges separately in due course. It is requested to take the same on your records.
31-Jan-22	Please find enclosed herewith Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter and nine months ended 31st December, 2021 along with Limited Review report thereon
31-Jan-22	Outcome of Board Meeting
31-Jan-22	Pursuant to the provisions of Regulation 32 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 31st December, 2021. Request you to take the same on your records.
31-Jan-22	This has reference to the captioned subject and our earlier communication w.r.t. a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 31st December, 2021. Kindly find attached herewith, a revised / corrected Statement of deviation(s) or variation(s). In the earlier statement of deviation(s) or variation(s) the amount raised was wrongly mentioned as INR 400 Million instead of INR 400 Crores. Kindly take the revised disclosure on your records.
31-Jan-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a Press Release on Unaudited Financial Results of the Company for the quarter and nine months ended on 31st December, 2021. Request you to take the same on your records.
2-Feb-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Unaudited Financial Results of the Company for the quarter and nine months ended on 31st December, 2021, published in Financial Express (All Editions) and Lokсатта (Pune Edition), both dated on 02nd February, 2022. Financial Statement for the quarter and nine months ended as mentioned above has also been published on website (www.krsnaadiagnostics.com) of the Company. Request you to take the same on your records.
2-Feb-22	Q3FY2022 Earnings Presentation
8-Feb-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Department of Medical Health & Family Welfare Government of Uttar Pradesh has awarded a Tender for providing CT Scan Services in the 6 District Hospitals in the State of Uttar Pradesh to the Company.
8-Feb-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Health Department, U.T., Chandigarh has awarded a Tender for Development, Operation and Maintenance of Radiology Imaging Diagnostic Centre in The Government Multi Speciality Hospital, Sector - 16, Chandigarh (GMSH-16) on Public Private Partnership (PPP) basis.
9-Feb-22	The transcript of the Q3FY22 Earnings Conference Call conducted on 03rd February, 2022.
11-Jan-22	Inauguration of Diagnostics Center at Bilaspur, Himachal Pradesh.
12-Feb-22	Pursuant to Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have attached herewith, a Report of Monitoring Agency i.e. ICICI Bank Limited for the quarter ended 31st December, 2021. You are requested to take the same on your record
21-Feb-22	Winning of Tender for providing Diagnostic / Laboratory Services in H.P. Govt. Health Institutions in entire State of Himachal Pradesh to the Company.

Notes:

The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and/or www.nseindia.com

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and/or the National Stock Exchange of India Limited ("NSE") and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement.